Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
Abdul M. Majzoub, Tarek Nayfeh, Abbey Barnard, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 7, pp. 880-889
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Mary E. Rinella, Brent A. Neuschwander‐Tetri, Mohammad Shadab Siddiqui, et al.
Hepatology (2023) Vol. 77, Iss. 5, pp. 1797-1835
Open Access | Times Cited: 1159
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Frank Tacke, Tobias Puengel, Rohit Loomba, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 552-566
Closed Access | Times Cited: 165
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
Monica A. Tincopa, Quentin M. Anstee, Rohit Loomba
Cell Metabolism (2024) Vol. 36, Iss. 5, pp. 912-926
Closed Access | Times Cited: 35
Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
J Bernhard, L Galli, Walter S. Speidl, et al.
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Open Access | Times Cited: 2
PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Naomi F. Lange, Vanessa Graf, Cyrielle Caussy, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4305-4305
Open Access | Times Cited: 54
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 53
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
Cheng Han Ng, Jieling Xiao, Wen Hui Lim, et al.
Hepatology (2022) Vol. 75, Iss. 6, pp. 1647-1661
Closed Access | Times Cited: 52
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
Anders Mellemkjær, Mikkel Breinholt Kjær, David Haldrup, et al.
European Journal of Internal Medicine (2023) Vol. 122, pp. 28-34
Open Access | Times Cited: 37
Dietary and lifestyle oxidative balance scores are independently and jointly associated with nonalcoholic fatty liver disease: a 20 years nationally representative cross-sectional study
Yuanbin Liu, Mingkai Chen
Frontiers in Nutrition (2023) Vol. 10
Open Access | Times Cited: 24
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Vincent Chen, Timothy R. Morgan, Yaron Rotman, et al.
Hepatology (2024)
Open Access | Times Cited: 16
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis
Rutao Lin, Qinmei Sun, Xin Xin, et al.
Metabolism (2024) Vol. 161, pp. 156043-156043
Closed Access | Times Cited: 9
Fecal Microbiota Transplantation in NAFLD Treatment
Ludovico Abenavoli, Valentina Maurizi, Emanuele Rinninella, et al.
Medicina (2022) Vol. 58, Iss. 11, pp. 1559-1559
Open Access | Times Cited: 33
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
Bertrand Cariou
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. S2, pp. 15-27
Closed Access | Times Cited: 32
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease
Stergios A. Pοlyzos, Dimitrios G. Goulis, Όλγα Γιουλεμέ, et al.
Current Obesity Reports (2022) Vol. 11, Iss. 3, pp. 166-179
Closed Access | Times Cited: 29
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
Minjeong Park, Hayeon Kim, Myeong Gyu Kim, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 693-704
Open Access | Times Cited: 20
AGER1 deficiency-triggered ferroptosis drives fibrosis progression in nonalcoholic steatohepatitis with type 2 diabetes mellitus
Yihui Gong, Zijun Liu, Yuanyuan Zhang, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 20
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
Rutao Lin, Jianghua Zhou, Qinmei Sun, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. 7, pp. 802-811
Closed Access | Times Cited: 8
The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
Jie Zhao, Baozhen Li, Kai Zhang, et al.
Medicine (2024) Vol. 103, Iss. 7, pp. e37271-e37271
Open Access | Times Cited: 7
Tyrosol attenuates NASH features by reprogramming the hepatic immune milieu
Daniela Gabbia, Katia Sayaf, Ilaria Zanotto, et al.
European Journal of Pharmacology (2024) Vol. 969, pp. 176453-176453
Open Access | Times Cited: 7
Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
Mohamed Mahmoud Marey, Mohamed Mohamed Belal, Abdelaziz A. Awad, et al.
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 6, pp. 102357-102357
Open Access | Times Cited: 6
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis
Benjamin Koh, Jieling Xiao, Cheng Han Ng, et al.
Hepatology (2024)
Closed Access | Times Cited: 6
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH
Jonathan G. Stine, Ian Schreibman, Alison Faust, et al.
Hepatology (2021) Vol. 76, Iss. 1, pp. 172-185
Open Access | Times Cited: 39
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Maria Zachou, Pagona Flevari, Narjes Nasiri‐Ansari, et al.
European Journal of Clinical Pharmacology (2023) Vol. 80, Iss. 1, pp. 127-150
Open Access | Times Cited: 16
Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)
Tobias Puengel, Frank Tacke
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 6, pp. 451-461
Closed Access | Times Cited: 15
Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms
James Westley Heinle, Kara DiJoseph, Angelo Sabag, et al.
Nutrients (2023) Vol. 15, Iss. 11, pp. 2452-2452
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top